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amount of cardiomyocytes undergoes apoptosis and is replaced by 
fibrous scar tissue. The relative unpredictability of acute cardiovas-
cular events, the high mortality rate and the absence of a durable 
post-ischemic treatment, endorse IHD to one of the most critical 
clinical hurdle of this century. The long-term survival of patients 
with heart failure is compromised by a series of complications as 
the massive proliferation of non-contractile fibrotic tissue in the in-
farcted areas. Additionally, after acute ischemic episodes, patients 
endure life-changing treatments ranging from daily medications to 
surgical interventions, e.g., pacemakers, stents, angioplasty or heart 
transplants. In this context, regenerative medicine can be consid-
ered as innovative and valid alternative. The identification of pro-
genitor cardiac cells within the adult human heart [1] encouraged 
the enthusiasm for cell-based regenerative therapies [2–4]. Moreo-
ver, the evidence that exogenous cells injected in the myocardium 
could minimally promote the formation of functional contractile 
tissue in the scarred areas provided an important contribution in 
directing the preclinical research towards the investigation of pos-
sible new treatments [5].Together with IHD, HVD represents a 
leading cause of mortality worldwide [6]. Different valve patholo-
gies are grouped under the HVD acronym, e.g., valve stenosis or 
prolapse; the latter are mainly caused by congenital heart valve de-
fects, infections or age-related pathological changes. New tech-
niques and prostheses for valve replacement have been introduced 
into clinical routine, increasing the range of treatment opportuni-
ties for the patients. Despite these efforts, today’s heart valve artifi-
cial prostheses are still associated with increasing risk of thrombo-
genic events, progressive degeneration, and calcification. In this 
scenario, regenerative medicine technologies such as tissue engi-
neering hold the potential to overcome the wide range of harmful 
limitations. The concept of heart valve tissue engineering encom-
passes the isolation, expansion, and seeding of patient-derived cells 
onto biodegradable scaffolds; this process is followed by in vitro 
culture and subsequent in vivo implantation of the final construct 
into the patient. The resulting bioengineered valve can potentially 
provide non-immunogenic, non-thrombogenic characteristics to-
gether with growth and remodeling properties. The research in the 
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Summary
In the effort of improving treatment for cardiovascular 
disease (CVD), scientists struggle with the lack of the re-
generative capacities of finally differentiated cardiovas-
cular tissues. In this context, the advancements in regen-
erative medicine contributed to the development of cell-
based therapies as well as macro- and micro-scale tis-
sue-engineering technologies. The current experimental 
approaches focus on different regenerative strategies 
including a broad spectrum of techniques such as parac-
rine-based stimulation of autologous cardiac stem cells, 
mesenchymal cell injections, 3D microtissue culture 
techniques and vascular tissue-engineering methods. 
These potential next-generation strategies are leading 
the way to a revolution in addressing CVD, and numer-
ous studies are now undertaken to assess their thera-
peutic value. With this review, we provide an update on 
the current research directions, on their major chal-
lenges, limitations, and achievements.
© 2016 S. Karger GmbH, Freiburg
Introduction 
Cardiovascular disease (CVD) includes a plethora of disorders 
affecting the cardiovascular system comprising, among others, 
heart failure (HF) and heart valve disease (HVD). Frequently, HF is 
caused by coronary artery occlusion and can lead to acute ischemic 
episodes (ischemic heart disease; IHD). Due to poor or absent post-
ischemic reperfusion of the infarcted myocardial areas, a significant 
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field is now focusing on new cell sources and new biomaterials; the 
optimal combination of these two factors could indeed contribute 
in raising the versatility and extending the horizons of the field of 
heart valve tissue engineering. 
Regenerative Technologies for Heart Failure
Despite the recent advances of basic research in the field, the 
detailed architecture of cardiac repair response upon ischemia is 
currently not clear. The presence of progenitor cells capable of a 
local and limited regenerative activity in the adult heart inspired 
the study and development of both i) cell-based technologies and 
ii) strategies for paracrine stimulation of the resident cardiac pro-
genitor cells. The next paragraphs will introduce and discuss both 
regenerative approaches. 
Cell-Based Regenerative Technologies: From Single Cell to  
Bioengineered Microtissues 
Over the past decades preclinical and clinical investigations of 
cell-based technologies for the treatment of the infarcted heart 
have been carried out. Different cell candidates were evaluated in 
vitro and are now under investigation for a possible therapeutic 
use. Examples are autologous in vitro-expanded cardiac progenitor 
cells (CPCs) and autologous adipose tissue- or bone marrow-de-
rived mesenchymal stem cells (MSCs) [7]. Although clinical trials 
based on the intra-myocardial injection of single-cell suspensions 
have been performed with mesenchymal autologous cells, the in-
terpretation of the results is controversial and roused questions 
and doubts regarding the power of the technology [8–10]. There is 
currently a consensus regarding the possible reasons for the single-
cell suspension therapy failure; the negative results are addressed to 
the scarce survival and retention of the cells at the level of the in-
farcted area [11]. The newest regenerative approaches aim at en-
hancing survival, grafting, and retention abilities of the injected 
cells using different methodologies. An example is provided by the 
cutting-edge bioengineered microtissue technology. Microtissues 
are scaffold-free tissue-engineered spheroids generated via hanging 
drop technique. These microstructures are reproducible with dif-
ferent cell types like CPCs, bone marrow- and adipose tissue-de-
rived MSCs [4] and have been tested in a pilot study on infarcted 
porcine models exhibiting promising results [12]. Other methods 
currently investigated for increasing cell retention in the infarcted 
areas include i) the combination of single cell suspensions with na-
noparticles loaded with functional agents [13], ii) the injection of a 
compact mixture of cells pre-cultured in hydrogels [14], or iii) the 
injection of cell-free hydrogels functionalized with paracrine me-
diators [15]. 
Paracrine Stimulation of Resident Progenitor Cells
The self-regenerative ability of the adult heart is per se ineffi-
cient to stimulate the functional replacement of necrotic areas and 
prevent the formation of fibrous tissue after myocardial infarction. 
Regenerative mechanisms demand tailored triggers that are pro-
vided by cell-cell communication. It is known that epicardium and 
endocardium share a communication network based on vesicular 
exchange [16]; cells can indeed exchange information by packing 
and delivering ribonucleic acids and proteins within microvesicles 
known as exosomes (EVs) [17–19]. A branch of recently developed 
regenerative technologies adopted this mechanism of cell-cell com-
munication to stimulate and increase the physiological regenera-
tive processes upon injury. The vesicular content of EVs varies ac-
cording to environmental clues (i.e., hypoxic conditions or acute 
myocardial infarction) and provides growth factors, anti-apoptotic 
and angiogenic as well as mitogenic signals. In detail, EVs are 
 predominantly enriched in microRNAs (miRNA), small non- 
coding RNA molecules with the function of post-transcriptional 
regulators [20]. Cardiomyocyte-specific extracellular factors and 
miRNAs (e.g. miR-1, miR-133, and miR-206) are key regulators of 
cardiac function and are released in high concentrations upon 
heart injury, exerting their regulatory role on the surrounding cells 
[21, 22]. The beneficial and synergic function of specific combina-
tions of miRNAs on CPCs has been proven together with the hy-
pothesis that miRNA families can selectively be secreted into the 
extracellular environment via exosomes [23, 24]. The recent EV-
inspired regenerative technologies focus either on i) the drug-ex-
erted stimulation of cardiac progenitors [25, 26] or ii) the in situ 
miRNA-targeted delivery [27]. Different studies contributed to the 
development of these technologies, like the in vitro and in vivo in-
vestigation of the secretome and extracellular vesicular content of 
MSCs. These studies led to the discovery of new cardioprotective 
molecules [28–31]. In this regard, Timmers et al. [30] showed in 
2007 the beneficial effects of MSC-conditioned medium upon in-
jection in a pig model of ischemia/reperfusion, reporting a signifi-
cant reduction in the ischemic myocardial area after the treatment. 
More recently, the secretome of human amniotic membrane-de-
rived MSCs was injected in infarcted rat models, leading to a re-
duction of the ischemic area and ventricular remodeling [28]. Al-
though these promising studies are still at the preclinical level, they 
have the potential to shorten the distance from clinical trials to a 
possible therapeutic approach in humans [32].
Regenerative Technologies for Heart Valve Disease 
The landscape of medical treatments for valvular disease is in 
constant expansion, providing hope in the possibility of improving 
HVD patients’ life expectancies. The most investigated and per-
formed treatment for late-stage valvular dysfunctions is, at the mo-
ment, heart valve replacement [6]. Different types of for valvular 
substitutes are available but the best option must be chosen consid-
ering different key parameters such as thromboresistance, implant-
ability, hemodynamics, and durability of the substitute device. The 
constant search for a durable, safe alternative for heart valve re-
placement stimulated a rapid development in the field of tissue en-
gineering. The bioengineered constructs are indeed autologous and 
potentially able to grow and adapt to the changing organ anatomy 
of a child, avoiding the hurdle of iterated surgery (fig. 1) [33, 34].
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Tissue Engineering Technologies for Heart Valve Replacement
Tissue engineering approaches are largely investigated in the 
field cardiovascular medicine and mainly rely on the fabrication of 
tissue-engineered blood vessels and heart valves. The key steps in 
today’s heart valve in vitro fabrication start with the isolation of 
cells from the patient. Cells are then expanded, characterized, and 
seeded onto biodegradable molds (fig. 1). Due to extracellular ma-
trix (ECM) production and concomitant scaffold degradation, the 
bioengineered heart valve is shaped and in vitro manufactured; po-
tentially ready to be implanted [35–37]. Advanced tissue engineer-
ing approaches are based on dynamic, pulsatile flow culturing 
strategies. These are fulfilled using in vitro bioreactor systems to 
simulate physiological mechanical stimuli provided by blood pres-
sure and flow [38]. Recently, a second, promising regenerative 
technology, known as in situ tissue engineering, has been investi-
gated. The latter is based on the hypothesis that the most appropri-
ate scaffold for tissue engineering is the ECM itself. According to 
this hypothesis, spontaneous scaffold-driven endogenous cell re-
cruitment and migration may occur in situ, leading to a complete 
ECM scaffold repopulation. To achieve this goal, native matrices 
are obtained through tissue decellularization and tested for in situ 
tissue engineering (fig. 2) [34, 39–41].
Biomaterials for Heart Valve Tissue Engineering
The chemical composition of the scaffold matrices employed 
for tissue engineering is crucial for the success of the valvular fabri-
cation process. The predominant scaffolding approach is based on 
the use of pore networks of biodegradable scaffolds [37, 42]. These 
porous networks are important for nutrient supply and are the 
common standard for the design of new biomaterials because they 
guarantee high reproducibility and low costs as well as remarkable 
mechanical strength and predictable physical properties. Many 
studies have investigated various fabrication techniques in order to 
generate novel structures for tissue engineering applications, e.g. 
polymers assembled with various electrospun designs [43–46]. To-
day’s attempts in developing scaffolds for tissue engineering are 
Fig. 1. Overview of 
the tissue engineering 
approach and scaffold 
matrices. Cells are 
seeded on support ma-
trix shaped like a tri-
leaflet heart valve. In 
the figure peculiar scaf-
fold materials for tissue 
engineering are sum-
marized and include  
i) synthetic matrices,  
ii) biological matrices, 
and iii) decellularized 
tissues. The final goal is 
the production of a tis-
sue engineered heart 
valve (TEHV) charac-
terized by optimal du-
rability, thromboresis-
tance, and hemody-
namic profile.
Fig. 2. Macroscopic appearance of decellularized 
in vitro grown tissue engineered heart valve. 
Adapted from Driessen et al. 2014 [34]. Macro-
scopic appearance of an implanted (A–C) and ex-
planted (D–F) decellularized in vitro grown heart 
valve in closed configuration (A, D), opened con-
figuration (B, E), and as cross section (C, F).
Mallone/Weber/HoerstrupTransfus Med Hemother 2016;43:291–296294
proceeding in two directions and are based on the use of more or 
less complex polymers from different sources that are either i) fully 
synthetic or based on ii) biological matrices. A huge variety of bio-
degradable synthetic polymers have been synthesized and histori-
cally proposed as suitable tissue engineering matrices [47], for ex-
ample, polyglycolic acid (PGA), polylactic acid (PLA), poly-4-hy-
droxybutyrate (P4HB) and polycaprolactone (PCL) all suitable for 
tissue engineering, being biodegradable and varying in manufac-
turing shapes (fig. 1). Among these, aliphatic polyester composite 
structures are considered as one of the best choices for tissue engi-
neering. One of their main features of interest resides in their rela-
tive resistance to fast hydrolytic degradation, which is a discrimi-
natory point given the obliged culture in aqueous media [48]. Their 
erosive degradation starts from the ester bonds in their polymeric 
backbone and is continued by random hydrolysis and concomitant 
enzymatic esterase activity [49, 50] while the degradation products 
are bio-resorbed in the common cellular metabolic pathways. The 
scaffold produced using biological matrices can be used alone or in 
combination with synthetic polymers [51]. The large class of bio-
scaffolds includes, among the others, polysaccharides such as algi-
nate and proteins such as collagen and fibrin [52]. These biomate-
rials were the subject of a recent revolution starting with the advent 
of 3D-bioprinting techniques. In 2013 Duan et al. [53] performed 
3D-bioprint living alginate/gelatin hydrogel aortic valves, incorpo-
rating within the biomaterial both smooth muscle cells and aortic 
valve leaflet interstitial cells, the main cell populations in the valve 
leaflets. However, despite the initial success of the biomatrices, the 
synthetic materials are still considered a better choice for tissue en-
gineering due to their high durability. Of great interest among bio-
materials used for heart valve tissue engineering are the commer-
cially produced polyhydroxylalkanoates, microbial polyesters that 
can be manufactured with the desired length and degradation time 
[54]. This family includes polymers such as poly-4-hydroxybu-
tyrate (P4HB) generally combined with other synthetic polymers 
(e.g. PGA) for the final manufacture of a hybrid scaffold. PGA-
P4HB is the today’s most used combination for the production of 
tri-leaflet heart valves due to the successful coupling of material-
related biophysical characteristics, joining the high porosity of 
PGA with the thermoplasticity of P4HB. The decellularized tissue-
derived matrices conclude the excursus on biomaterials for heart 
valve regenerative technologies. The possibility to use tissue-de-
rived templates made of naturally assembled networks of ECM is 
inevitably interesting as an alternative to the materials described 
above. One of the main unsolved questions is the matter of the 
donor source. The latter has to be properly chosen to avoid a pos-
sible immune response in the host or disease transmission [55]. 
Therefore, the choice of the donor tissue must be accurate; today’s 
most used decellularized scaffold matrices are derived from homo-
grafts or xenografts [56]. A recent study investigated the repopula-
tion capacity of decellularized tissue-engineered heart valves in a 
non-human primate model up to 8 weeks [39], showing a rapid 
cellular repopulation of the decellularized constructs and high re-
modeling capacities. This study underlines the strong translational 
power of this technology.
Cell Sources for Heart Valve Tissue Engineering
Other crucial variables to be considered for a fruitful in vitro 
tissue-engineered valvular production include i) the cell type used 
for the seeding onto the valvular molds, ii) the culture type, mean-
ing either single cell type cultures or co-culture systems, and iii) 
ECM production coupled with biomaterial degradation rates [57]. 
Additionally, cells should be of autologous origin, non-immuno-
genic, and possessing pronounced plasticity. A wide panel of cell 
types with such characteristics has been investigated for tissue en-
gineering, like vascular tissue, adipose tissue, umbilical cord 
blood, chorionic villi, amniotic fluid-derived cells, or cells directly 
differentiated from patients’ induced pluripotent stem cells 
(iPSCs). Cells derived from vascular tissues (e.g. from peripheral 
arteries or umbilical veins) are so far the cell types preferred for 
scaffold seeding for tissue engineered heart valve production [6]. 
Usually, two main cell populations are isolated from this tissue 
type: endothelial cells and myofibroblasts. The latter are responsi-
ble for the creation of a stable environment for the endothelial 
cells by depositing ECM, while endothelial cells generate a tight 
and confluent layer [33, 40]. Stem cells are one of today’s most in-
teresting options for tissue engineered valve production [37] due 
to their fast growth and extensive potential to differentiate to-
wards different cell fates. Among them, MSCs not only share im-
portant phenotypic traits with the valve interstitial cells but also 
retain a great cellular potency and can be isolated with minimally 
invasive interventions. This endorses MSCs as one of the most 
suitable stem cell candidates for valvular bioengineering. In recent 
years, another interesting cell source has become available. In 
2006 Yamanaka et al. [58] managed to reprogram adult fibroblasts 
to a pluripotent status, obtaining iPSCs. Due to their non-embry-
onic origin, the use of iPSCs for tissue engineering could poten-
tially overcome all ethical problems, allowing to create a patient-
specific valvular construct by differentiating the stem cells gener-
ated from autologous skin biopsy [59].
Conclusions 
The present review summarizes the most recent regenerative 
technologies developed for the treatment of CVD. In particular, it 
provides an overview of the regenerative strategies in the context of 
IHD and HVD. It is possible to identify few promising concepts 
that are drawing the future of the field. One of them is the idea of 
replacing/combining stem cell-based therapies for the infarcted 
heart with an intra-myocardial injection of a cardioprotective 
cocktail. Other intriguing concepts are i) the use of microtissues as 
a possible alternative to cell therapy performed with single-cell sus-
pensions and ii) the heart valve tissue engineering technology. The 
first is considered a promising cell delivery system for enhancing 
cellular engraftment and survival in the infarcted myocardium; the 
second aims at revolutionizing the field of heart valve replacement 
with the use of decellularized tissues for promoting in situ tissue 
regeneration.
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